NASDAQ:JSPR
Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. reported net income of −$75.8M in fiscal 2025. The diluted share count rose 31.4%.Summary generated from Jasper Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−230.3%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+31.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −37 | −51 | −69 | −76 | −84 |
| Net income | −31 | −38 | −64 | −71 | −76 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KOther events
Oct 7, 2026 - 8-KResults of a shareholder vote
Oct 5, 2026 - 8-K/AAmended current report
Oct 5, 2026 - 8-K/AAmended current report
Oct 1, 2026 - 8-KDirector or officer change
Sep 28, 2026 - DEF 14AProxy statement
Sep 4, 2026 - 8-KEntry into a material agreement
Aug 26, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026